Atreca to Present at Upcoming Virtual Investor Conferences
05 August 2021 - 6:30AM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage
biotechnology company focused on developing novel therapeutics
generated through a unique discovery platform based on
interrogation of the active human immune response, today announced
that it will present at the following upcoming virtual investor
conferences:
Wedbush PacGrow Healthcare ConferenceTuesday,
August 10, 2021Panel discussion time: 1:10 p.m. EDTPanel title:
Heavenly (anti)Bodies
Canaccord Genuity 41st
Annual Growth ConferenceThursday, August 12,
2021Fireside chat time: 3:00 p.m. EDT
A live audio webcast of the Canaccord presentation can be
accessed through the Events & Presentations section of the
Company's website at ir.atreca.com. An archived replay will be
available on the Company's website for 90 days following the live
presentation.
About Atreca, Inc. Atreca is a
biopharmaceutical company developing novel antibody-based
immunotherapeutics generated by its differentiated discovery
platform. Atreca’s platform allows access to an unexplored
landscape in oncology through the identification of unique
antibody-target pairs generated by the human immune system during
an active immune response against tumors. These antibodies provide
the basis for first-in-class therapeutic candidates, such as our
lead product candidate ATRC-101. A Phase 1b study evaluating
ATRC-101 in multiple solid tumor cancers is currently enrolling
patients. For more information on Atreca, please visit
www.atreca.com.
Forward-Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and typically are identified by use of terms such as
"continued," "anticipate," "potential," "expect," "believe,"
"planned," and similar words, although some forward-looking
statements are expressed differently. These statements include
those related to our strategy and future plans, including
statements regarding the development of ATRC-101 and our
preclinical, clinical and regulatory plans and the timing thereof.
Our actual results may differ materially from those indicated in
these forward-looking statements due to risks and uncertainties
related to the initiation, timing, progress and results of our
research and development programs, preclinical studies, clinical
trials, regulatory submissions, and other matters that are
described in our filings with the Securities and Exchange
Commission (SEC) and available on the SEC’s website at www.sec.gov,
including in the “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” sections
of our most recently filed annual report on Form 10-K and quarterly
report on Form 10-Q. Investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release, and we undertake no obligation
to update any forward-looking statement in this press release,
except as required by law.
ContactsAtreca, Inc.Herb CrossChief Financial
Officerinfo@atreca.comInvestors:Alex Gray, 650-779-9251, ext.
251agray@atreca.com
Media:Sheryl Seapy, 213-262-9390sseapy@w2ogroup.com
Source: Atreca, Inc.
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Jul 2024 to Aug 2024
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Aug 2023 to Aug 2024